Breaking News Instant updates and real-time market news.

BIIB

Biogen

$217.29

-9.42 (-4.16%)

07:17
03/25/19
03/25
07:17
03/25/19
07:17

Biogen announces $5B share repurchase program

On March 24, the Board of Directors of Biogen authorized a program to repurchase up to $5B of the company's common stock. The 2019 Share Repurchase Program does not have an expiration date. All share repurchases under the 2019 Share Repurchase Program will be retired. The 2019 Share Repurchase Program is in addition to the approximately $1.7B remaining under the share repurchase program authorized by the Board of Directors of the company in August 2018.

  • 25

    Mar

  • 24

    Apr

  • 30

    Apr

  • 01

    May

BIIB Biogen
$217.29

-9.42 (-4.16%)

03/22/19
MSCO
03/22/19
DOWNGRADE
Target $210
MSCO
Underweight
Morgan Stanley double downgrades Biogen to Underweight after Alzheimer's failure
As previously reported, Morgan Stanley analyst Matthew Harrison downgraded Biogen to Underweight from Overweight after the company announced the failure of two Alzheimer's disease trials, noting that his optimism on Alzheimer's was "completely wrong." Without that potential upside driver, Harrison does not expect a near-term recovery in Biogen shares, though he admits that a significant acquisition that accelerates topline growth "represents the major risk" to his Underweight thesis. Absent M&A, he sees no near-to-midterm upside driver and believes downside risks from Spinraza competition and challenges to Tecfidera's patents are exposed. Harrison lowered his price target on Biogen shares to $210 from $401.
03/22/19
JEFF
03/22/19
NO CHANGE
Target $250
JEFF
Hold
Biogen shares still not trading at 'Uber-Bear case' yet, says Jefferies
Jefferies analyst Michael Yee lowered his price target for Biogen to $250 from $380 and maintains a Hold rating on the shares following yesterday's Alzheimer's failure. The stock, while "cheap," is not trading at an "Uber-Bear case" yet, Yee tells investors in a research note. The analyst sees downside risk to $175-$200 per share amid the "binary overhang and uncertainty" from the Tecfidera inter partes review. Further, Yee believes Spinraza consensus estimates still have to come down. He maintains a Hold rating on Biogen.
03/22/19
03/22/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PPG (PPG) downgraded to Underweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas saying PPG shares have been drifting higher in 2019 as the market continues to prefer higher quality and less cyclical materials companies, however general economic business conditions are "arguably weaker than they have been because of decreased rates of economic growth in China and in Europe." 2. Sherwin-Williams (SHW) downgraded to Neutral from Overweight at JPMorgan with analyst Jeffrey Zekauskas citing valuation. 3. Booking Holdings (BKNG) downgraded to Neutral from Outperform at Wedbush with analyst James Hardiman stating that he believes the company's dominant position in Europe will be favorable in the long term, but is likely to represent a liability in 2019 as it is could amplify risks of earnings revisions and multiple compression. 4. Biogen (BIIB) downgraded to Underweight from Overweight at Morgan Stanley with analyst Matthew Harrison citing the failure of two Alzheimer's disease trials and noting that his optimism on Alzheimer's was "completely wrong." 5. Lululemon (LULU) downgraded to Neutral from Outperform at Wedbush with analyst Jen Redding saying that while she continues to see lululemon as best in class among specialty retailers, she is moving to the sidelines in anticipation of potentially less margin upside ahead, based on insights from proprietary data products. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/25/19
HCWC
03/25/19
NO CHANGE
Target $300
HCWC
Buy
Biogen price target lowered to $300 from $363 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein lowered his price target for Biogen to $300 from $363 after the company and Eisai decided to stop clinical trials of aducanumab based on the futility results of the interim analysis of the Phase 3 trials. Investor focus will likely now shift to the pipeline growth and defense of Biogen's multiple sclerosis franchise, Fein tells investors in a research note. He thinks Spinraza should continue to drive revenue growth in the near-term and believes Biogen has sufficient financial means to continue investing in the pipeline to support the long-term growth of the company. The analyst keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

WFT

Weatherford

$0.00

(0.00%)

18:49
12/13/19
12/13
18:49
12/13/19
18:49
Hot Stocks
Weatherford completes financial restructuring, emerges from Chapter 11 »

Weatherford announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$57.71

-0.81 (-1.38%)

18:40
12/13/19
12/13
18:40
12/13/19
18:40
Hot Stocks
Centene CEO: Our big markets are growing, we're gaining share »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

LYV

Live Nation

$64.24

-5.205 (-7.50%)

, ZBRA

Zebra Technologies

$257.82

-0.32 (-0.12%)

18:29
12/13/19
12/13
18:29
12/13/19
18:29
Hot Stocks
S&P announces changes to S&P 400, 500, 600 indices »

S&P Dow Jones Indices…

LYV

Live Nation

$64.24

-5.205 (-7.50%)

ZBRA

Zebra Technologies

$257.82

-0.32 (-0.12%)

STE

Steris

$151.93

-1.745 (-1.14%)

AMG

Affiliated Managers

$85.18

-1.77 (-2.04%)

TRIP

TripAdvisor

$29.24

-0.2 (-0.68%)

MAC

Macerich

$26.04

-0.46 (-1.74%)

LOPE

Grand Canyon

$89.24

-0.86 (-0.95%)

LEA

Lear

$129.43

-0.84 (-0.64%)

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

UNT

Unit Corp.

$0.83

-0.0626 (-6.98%)

FTR

Frontier Communications

$0.68

0.0315 (4.84%)

ARWR

Arrowhead

$66.47

-0.91 (-1.35%)

GVA

Granite Construction

$26.21

-1.335 (-4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 23

    Mar

PLAN

Anaplan

$51.80

1.44 (2.86%)

18:23
12/13/19
12/13
18:23
12/13/19
18:23
Hot Stocks
Anaplan CEO: Digitization has really started to accelerate »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPX

WPX Energy

$10.92

-0.24 (-2.15%)

18:08
12/13/19
12/13
18:08
12/13/19
18:08
Periodicals
WPX Energy in talks to acquire Felix Energy assets for $2.5B, Bloomberg says »

WPX Energy is in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

HLIT

Harmonic

$7.94

-0.25 (-3.05%)

17:47
12/13/19
12/13
17:47
12/13/19
17:47
Hot Stocks
Harmonic CFO sells 28K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$32.84

(0.00%)

17:36
12/13/19
12/13
17:36
12/13/19
17:36
Hot Stocks
Breaking Hot Stocks news story on Horizon Pharma »

Horizon Pharma up 9.6% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 08

    Mar

AMRN

Amarin

$24.12

1.12 (4.87%)

17:33
12/13/19
12/13
17:33
12/13/19
17:33
Hot Stocks
Breaking Hot Stocks news story on Amarin »

Amarin rises 1.4% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

THMO

ThermoGenesis

$2.88

(0.00%)

17:31
12/13/19
12/13
17:31
12/13/19
17:31
Syndicate
Breaking Syndicate news story on ThermoGenesis »

ThermoGenesis files $30M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

17:30
12/13/19
12/13
17:30
12/13/19
17:30
Hot Stocks
Breaking Hot Stocks news story on Amarin 

Amarin trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

QTNT

Quotient

$8.60

-0.165 (-1.88%)

17:28
12/13/19
12/13
17:28
12/13/19
17:28
Syndicate
Breaking Syndicate news story on Quotient »

Quotient files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARWR

Arrowhead

$66.47

-0.91 (-1.35%)

, GVA

Granite Construction

$26.21

-1.335 (-4.85%)

17:27
12/13/19
12/13
17:27
12/13/19
17:27
Hot Stocks
Breaking Hot Stocks news story on Arrowhead, Granite Construction »

Arrowhead to replace…

ARWR

Arrowhead

$66.47

-0.91 (-1.35%)

GVA

Granite Construction

$26.21

-1.335 (-4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

, SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

17:25
12/13/19
12/13
17:25
12/13/19
17:25
Hot Stocks
Oasis, Southwestern to replace Unit Corp., Frontier in S&P 600 at open on 12/23 »

Oasis Petroleum (OAS) and…

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

UNT

Unit Corp.

$0.83

-0.0626 (-6.98%)

FTR

Frontier Communications

$0.68

0.0315 (4.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

AMRN

Amarin

$24.12

1.12 (4.87%)

17:24
12/13/19
12/13
17:24
12/13/19
17:24
Hot Stocks
Amarin raises guidance after FDA approves Vascepa »

Amarin (AMRN) shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

LOPE

Grand Canyon

$89.24

-0.86 (-0.95%)

, LEA

Lear

$129.43

-0.84 (-0.64%)

17:22
12/13/19
12/13
17:22
12/13/19
17:22
Hot Stocks
Grand Canyon, Lear to replace Oasis, Southwestern in S&P 400 at open on 12/23 »

Grand Canyon Education…

LOPE

Grand Canyon

$89.24

-0.86 (-0.95%)

LEA

Lear

$129.43

-0.84 (-0.64%)

OAS

Oasis Petroleum

$2.68

-0.295 (-9.93%)

SWN

Southwestern Energy

$2.00

-0.12 (-5.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

RTN

Raytheon

$217.31

-0.93 (-0.43%)

17:20
12/13/19
12/13
17:20
12/13/19
17:20
Hot Stocks
Raytheon awarded $123.53M Navy contract modification »

Raytheon was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYV

Live Nation

$64.24

-5.205 (-7.50%)

, ZBRA

Zebra Technologies

$257.82

-0.32 (-0.12%)

17:19
12/13/19
12/13
17:19
12/13/19
17:19
Hot Stocks
Live Nation, Zebra Technologies, Steris to move to S&P 500 at open on 12/23 »

Live Nation (LYV), Zebra…

LYV

Live Nation

$64.24

-5.205 (-7.50%)

ZBRA

Zebra Technologies

$257.82

-0.32 (-0.12%)

STE

Steris

$151.93

-1.745 (-1.14%)

AMG

Affiliated Managers

$85.18

-1.77 (-2.04%)

TRIP

TripAdvisor

$29.24

-0.2 (-0.68%)

MAC

Macerich

$26.04

-0.46 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

BAESY

BAE Systems

$0.00

(0.00%)

17:15
12/13/19
12/13
17:15
12/13/19
17:15
Hot Stocks
BAE Systems awarded $249.15M Army contract modification »

BAE Systems was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WST

West Pharmaceutical

$146.32

-0.14 (-0.10%)

17:02
12/13/19
12/13
17:02
12/13/19
17:02
Hot Stocks
West Pharmaceutical announces 848K share repurchase authorization »

On December 10, 2019, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

17:02
12/13/19
12/13
17:02
12/13/19
17:02
Earnings
Amarin sees FY20 revenue $650M-$700M, consensus $654.55M »

With respect to 2020,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

IBIO

iBio

$0.22

-0.0179 (-7.43%)

17:01
12/13/19
12/13
17:01
12/13/19
17:01
Hot Stocks
iBio receives NYSE noncompliance notice »

iBio, Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APLT

Applied Therapeutics

$21.23

0.29 (1.38%)

16:59
12/13/19
12/13
16:59
12/13/19
16:59
Syndicate
Breaking Syndicate news story on Applied Therapeutics »

Applied Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

16:59
12/13/19
12/13
16:59
12/13/19
16:59
Earnings
Amarin raises FY19 revenue view to $410M-$425M from $380M-$420M 

FY19 consensus $410.25M.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

BIO

Bio-Rad

$354.69

-8.005 (-2.21%)

16:56
12/13/19
12/13
16:56
12/13/19
16:56
Hot Stocks
Bio-Rad progressing from ransomware attack recovery detected on Dec 5th »

Bio-Rad Laboratories…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$24.12

1.12 (4.87%)

16:50
12/13/19
12/13
16:50
12/13/19
16:50
Hot Stocks
Amarin confirms FDA approval of Vascepa »

Amarin announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.